Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$118.49

0.93 (0.79%)

, PFE

Pfizer

$32.50

-0.16 (-0.49%)

17:49
10/17/16
10/17
17:49
10/17/16
17:49

J&J trades lower after Pfizer announces availability of Remicade biosimilar

Shares of Johnson & Johnson (JNJ) are fractionally lower, down 0.41%, or 49c to $118 per share in after-hours trading after Pfizer (PFE) announced that the company will begin shipment of INFLECTRA for injection, a biosimilar of REMICADE to wholesalers in the United States in late November 2016.

JNJ

Johnson & Johnson

$118.49

0.93 (0.79%)

PFE

Pfizer

$32.50

-0.16 (-0.49%)

  • 18

    Oct

  • 22

    Oct

  • 26

    Oct

  • 01

    Nov

  • 06

    Nov

JNJ Johnson & Johnson
$118.49

0.93 (0.79%)

08/24/16
JEFF
08/24/16
NO CHANGE
Target $210
JEFF
Buy
Cooper Companies estimates raised at Jefferies after doctor survey
Jefferies analyst Anthony Petrone reports that the firm's survey of 52 new optometry practices suggest continued gains in dailies and stable share in monthlies for Cooper Companies (COO) and that Johnson & Johnson's (JNJ) Acuvue Vita is off to slow start. Based on the survey results, and a "significant" foreign exchange tailwind, Petrone raised his estimates for Cooper and increased his price target on the shares to $210 from $190. The firm has a Buy rating on Cooper shares.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.
10/07/16
RBCM
10/07/16
NO CHANGE
RBCM
Johnson & Johnson weakness creates buying opportunity, says RBC Capital
RBC Capital analyst Glenn Novarro says that Johnson & Johnson underperformed the market in Q3 due to a number of factors including Remicade biosimilar risk and the pharma pricing debate. The analyst says that "these concerns are manageable/overblown," and he expects the company to report strong Q3 results, driven by a strong pharma performance. Novoroo expects the company's Q3 revenue to come in slightly above expectations, and he predicts that the company will narrow its 2016 EPS guidance to the high end of the previous range. The analyst recommends buying the stock. He keeps a $133 price target and Outperform rating on the shares.
PFE Pfizer
$32.50

-0.16 (-0.49%)

09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.
10/07/16
ROTH
10/07/16
NO CHANGE
Target $160
ROTH
Buy
ICU Medical price target raised to $160 from $132 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for ICU Medical (ICUI) to $160 from $132 after the company announced an agreement to acquire Hospira Infusion Systems from Pfizer (PFE) for $1B. The analyst is overall positive on the deal as it removes the long-standing customer concentration overhang and grows ICU Medical into a legitimate pure-play infusion therapy company with a complete product portfolio. The company also preannounced Q3 preliminary results above expectations, he notes. Lewis reiterates a Buy rating on ICU Medical's shares.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
10/13/16
10/13/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Buy from Conviction Buy at Goldman with analyst Jami Rubin saying disappointing CM-26 data adds a greater level of uncertainty to future trials. 2. Pfizer (PFE) downgraded to Hold from Buy at Jefferies with analyst Jeffrey Holford citing a lack of positive catalysts. 3. Coach (COH) downgraded to Mixed from Positive at OTR Global citing checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers. 4. E-Trade (ETFC) downgraded to Neutral from Buy at BofA/Merrill. 5. Deckers Brands (DECK) downgraded to Negative from Neutral at Susquehanna with analyst Sam Poser saying he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

FSNUY

Fresenius SE

$20.56

0.89 (4.52%)

, AKRX

Akorn

$32.72

-0.19 (-0.58%)

16:58
04/24/17
04/24
16:58
04/24/17
16:58
Hot Stocks
Breaking Hot Stocks news story on Fresenius SE, Akorn »

Fresenius to acquire…

FSNUY

Fresenius SE

$20.56

0.89 (4.52%)

AKRX

Akorn

$32.72

-0.19 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSNUY

Fresenius SE

$20.56

0.89 (4.52%)

, AKRX

Akorn

$32.72

-0.19 (-0.58%)

16:58
04/24/17
04/24
16:58
04/24/17
16:58
Periodicals
Breaking Periodicals news story on Fresenius SE, Akorn »

Fresenius SE to acquire…

FSNUY

Fresenius SE

$20.56

0.89 (4.52%)

AKRX

Akorn

$32.72

-0.19 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$53.65

0.65 (1.23%)

16:56
04/24/17
04/24
16:56
04/24/17
16:56
Hot Stocks
Wells Fargo: 'Pleased' with Fed, FDIC findings, committed to 'sound resolution' »

Wells Fargo issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

OMED

OncoMed

$3.77

0.04 (1.07%)

16:48
04/24/17
04/24
16:48
04/24/17
16:48
Hot Stocks
OncoMed announces workforce reduction »

OncoMed Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ESRX

Express Scripts

$67.25

0.79 (1.19%)

, ANTM

Anthem

$168.41

0.61 (0.36%)

16:46
04/24/17
04/24
16:46
04/24/17
16:46
Hot Stocks
Express Scripts down 12% after contract with Anthem unlikely to be renewed »

In after hours trading,…

ESRX

Express Scripts

$67.25

0.79 (1.19%)

ANTM

Anthem

$168.41

0.61 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 18

    May

  • 06

    Jun

OI

Owens-Illinois

$21.34

0.83 (4.05%)

16:46
04/24/17
04/24
16:46
04/24/17
16:46
Earnings
Owens-Illinois sees FY17 EPS $2.40-$2.50, consensus $2.43 »

The Company continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ESRX

Express Scripts

$67.25

0.79 (1.19%)

16:45
04/24/17
04/24
16:45
04/24/17
16:45
Hot Stocks
Breaking Hot Stocks news story on Express Scripts »

Express Scripts trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 06

    Jun

OI

Owens-Illinois

$21.34

0.83 (4.05%)

16:44
04/24/17
04/24
16:44
04/24/17
16:44
Earnings
Owens-Illinois reports Q1 EPS 58c, consensus 53c »

Reports Q1 revenue $1.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

WFC

Wells Fargo

$53.65

0.65 (1.23%)

16:44
04/24/17
04/24
16:44
04/24/17
16:44
Hot Stocks
Federal Reserve, FDIC approve revised Wells Fargo living will »

The Federal Deposit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

ESRX

Express Scripts

$67.25

0.79 (1.19%)

, ANTM

Anthem

$168.41

0.61 (0.36%)

16:43
04/24/17
04/24
16:43
04/24/17
16:43
Hot Stocks
Express Scripts CEO: 'Perplexed' by potential loss of Anthem contract »

Says Anthem deal is…

ESRX

Express Scripts

$67.25

0.79 (1.19%)

ANTM

Anthem

$168.41

0.61 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 18

    May

  • 06

    Jun

SMMF

Summit Financial Group

$23.00

0.28 (1.23%)

16:41
04/24/17
04/24
16:41
04/24/17
16:41
Hot Stocks
Summit Financial Group announces resolution of litigation »

Summit Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$80.05

0.77 (0.97%)

, ESRX

Express Scripts

$67.25

0.79 (1.19%)

16:39
04/24/17
04/24
16:39
04/24/17
16:39
Hot Stocks
Breaking Hot Stocks news story on CVS Health, Express Scripts, Anthem »

CVS up 2% after Express…

CVS

CVS Health

$80.05

0.77 (0.97%)

ESRX

Express Scripts

$67.25

0.79 (1.19%)

ANTM

Anthem

$168.41

0.61 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 02

    May

  • 10

    May

  • 18

    May

  • 06

    Jun

NVS

Novartis

$74.61

1.21 (1.65%)

16:39
04/24/17
04/24
16:39
04/24/17
16:39
Hot Stocks
Novartis expands pact with Amgen to commercialize AMG 334 for migraine »

Novartis (NVS) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 06

    Jun

  • 26

    Jun

HMN

Horace Mann

$39.25

0.15 (0.38%)

16:39
04/24/17
04/24
16:39
04/24/17
16:39
Earnings
Horace Mann reports Q1 EPS 37c with items, may not compare to consensus 55c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

WNC

Wabash

$20.36

0.64 (3.25%)

16:36
04/24/17
04/24
16:36
04/24/17
16:36
Earnings
Breaking Earnings news story on Wabash »

Wabash sees FY17 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 23

    May

  • 24

    May

WFC

Wells Fargo

$53.65

0.65 (1.23%)

16:36
04/24/17
04/24
16:36
04/24/17
16:36
Periodicals
Breaking Periodicals news story on Wells Fargo »

Fed clears Wells Fargo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

WNC

Wabash

$20.36

0.64 (3.25%)

16:35
04/24/17
04/24
16:35
04/24/17
16:35
Earnings
Wabash reports Q1 EPS 32c, consensus 27c »

Reports Q1 revenue $363M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 23

    May

  • 24

    May

BCR

C.R. Bard

$302.41

49.34 (19.50%)

, BDX

Becton Dickinson

$177.07

-8.22 (-4.44%)

16:34
04/24/17
04/24
16:34
04/24/17
16:34
General news
On The Fly: Top stock stories for Monday »

Stocks began the session…

BCR

C.R. Bard

$302.41

49.34 (19.50%)

BDX

Becton Dickinson

$177.07

-8.22 (-4.44%)

PPG

PPG

$108.01

2.07 (1.95%)

AKZOY

AkzoNobel

$29.73

1.77 (6.33%)

ARNC

Arconic

$26.10

0.1 (0.38%)

HAS

Hasbro

$101.70

5.67 (5.90%)

SRPT

Sarepta

$34.02

1.41 (4.32%)

W

Wayfair

$43.48

-2.48 (-5.40%)

AMZN

Amazon.com

$907.41

8.88 (0.99%)

HLX

Helix Energy

$6.06

-1.03 (-14.53%)

HAL

Halliburton

$46.75

-0.31 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 01

    May

  • 01

    May

  • 03

    May

  • 04

    May

  • 09

    May

  • 16

    May

  • 17

    May

  • 17

    May

  • 18

    May

  • 23

    May

  • 31

    May

  • 06

    Jun

PII

Polaris Industries

$83.14

1.28 (1.56%)

16:34
04/24/17
04/24
16:34
04/24/17
16:34
Hot Stocks
Polaris Industries discontinuing manufacturing at its plant in Milford, Iowa »

Polaris Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

UIS

Unisys

$11.15

0.2 (1.83%)

16:33
04/24/17
04/24
16:33
04/24/17
16:33
Earnings
Unisys sees FY17 revenue $2.65B-2.75B, consensus $2.71B »

Sees FY17 non-GAAP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 26

    Apr

CVRS

Corindus

16:33
04/24/17
04/24
16:33
04/24/17
16:33
Hot Stocks
Corindus announces strategic partnership with BLOXR »

Corindus Vascular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

HSTM

HealthStream

$23.62

-0.08 (-0.34%)

16:32
04/24/17
04/24
16:32
04/24/17
16:32
Earnings
HealthStream backs FY17 consolidated revenue growth view of 10%-14% »

Consensus $252.3M. Backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

UIS

Unisys

$11.15

0.2 (1.83%)

16:32
04/24/17
04/24
16:32
04/24/17
16:32
Earnings
Unisys reports Q1 EPS (65c), consensus (60c) »

Reports Q1 revenue $665M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 26

    Apr

AMGN

Amgen

$163.14

2.73 (1.70%)

, NVS

Novartis

$74.61

1.21 (1.65%)

16:32
04/24/17
04/24
16:32
04/24/17
16:32
Hot Stocks
Amgen announces expanded collarboration with Novartis for erenumab »

Amgen (AMGN) announced an…

AMGN

Amgen

$163.14

2.73 (1.70%)

NVS

Novartis

$74.61

1.21 (1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 06

    Jun

  • 26

    Jun

  • 19

    Jul

  • 14

    Aug

HSTM

HealthStream

$23.62

-0.08 (-0.34%)

16:31
04/24/17
04/24
16:31
04/24/17
16:31
Earnings
HealthStream reports Q1 EPS 4c, consensus 4c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.